Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings

Abstract

Aim: investigate the possible anti-psoriatic effect of ivermectin in mice based on observational and histopathological outcomes and biomarkers. Methods: Sixty male Swiss Albino Mice were divided into six groups (Groups I–VI); each group contained ten mice with shaved dorsal skin. The clinical, pathological, and laboratory effects were measured. Results: Topical Ivermectin significantly decreased vascular endothelial growth factor levels. At the same time, the combination of ivermectin plus Clobetasol showed a more significant reduction in tumor necrosis factor-alpha (TNF-α) and Interleukin-17 (IL-17) levels. Regarding the Interleukin-10 (IL-10) level, the Ivermectin and Ivermectin/Clobetasol combination groups showed a significant increase in IL-10. Conclusion: Topical Ivermectin’s anti-psoriasis activity increases IL-10 levels and could be used efficiently to alleviate psoriatic symptoms. Its combination treatment with Clobetasol holds promise for the management of psoriasis.

Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis

“…The prototype of imiquimod-aggravated psoriasis in mice is more broadly utilized for experiments on molecular processes, antipsoriatic medication development, and percutaneous drug absorption. 70,75,126,127 In tandem with past investigations, an 8day administration of imiquimod to mouse dorsal skinfolds gave rise to psoriasiform plaques characterized by redness, desquamation, and acanthosis, along with upregulated expression of pro-inflammatory, angiogenic, and oxidative parameters. 31,32,38,72 It was documented that the skin lesions in the imiquimodapplied murine model, involving redness, acanthosis/thickening, scaling/flaking, cutaneous histology modifications (Munro's abscesses, hyperkeratosis, parakeratosis), and sproutingangiogenesis, alongside an inflammatory penetration made up of T lymphocytes, mast cells, neutrophils, and dendritic cell populations, were remarkably similar to those observed in human psoriasis vulgaris.…”

“…The prototype of imiquimod-aggravated psoriasis in mice is more broadly utilized for experiments on molecular processes, antipsoriatic medication development, and percutaneous drug absorption. ,,, In tandem with past investigations, an 8-day administration of imiquimod to mouse dorsal skinfolds gave rise to psoriasiform plaques characterized by redness, desquamation, and acanthosis, along with upregulated expression of pro-inflammatory, angiogenic, and oxidative parameters. ,,, …”

“…An assessment score of 0 suggests that there is no visible lesion, 1 suggests that the epidermis is only slightly pink, 2 suggests that it appears pink, 3 suggests that it appears red, and 4 suggests that it is dark red. The sum of total scoring for erythema, scaling, and thickness was employed to assess the intensity of cumulative PASI on a scale from 0 to 12. − …”